CA
DNA icon

Claro Advisors’s Ginkgo Bioworks DNA Stock Holding History

Claro Advisors’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,500
Closed -$238K – 331
2022
Q3 		$238K Hold
2,500
– – 0.09% 226
2022
Q2 		$238K Buy
2,500
+950
+61% +$116K 0.09% 226
2022
Q1 		$515K Hold
1,550
– – 0.19% 140
2021
Q4 		$515K Buy
1,550
+300
+24% +$143K 0.19% 140
2021
Q3 		$580K Buy
+1,250
New +$609K 0.24% 119

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Claro Advisors's DNA Position: Q4 2022 in Review

Claro Advisors sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 2,500 shares — an estimated $238K sold.

Claro Advisors first reported a position in DNA in Q3 2021 and held it in 5 quarters. The position peaked at $580K in Q3 2021. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

  • Claro Advisors reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
  • Claro Advisors sold 2,500 Ginkgo Bioworks shares in Q4 2022, an estimated $238K.
  • Claro Advisors first reported a position in Ginkgo Bioworks in Q3 2021 and held it in 5 quarters.
  • Claro Advisors's Ginkgo Bioworks position peaked at $580K in Q3 2021.
  • 320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Claro Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.